AB&B BIO-TECH-B (02627) announced that the group anticipates reporting revenue of approximately RMB 4.46 billion to RMB 4.93 billion for the 2025 fiscal year. This represents an increase of about 71.8% to 89.9% compared to the revenue of RMB 2.6 billion recorded for the year ended December 31, 2024. The company also expects to report a net loss of approximately RMB 1.57 billion to RMB 1.97 billion for the 2025 fiscal year, which is a reduction of about 23.9% to 39.3% compared to the net loss of RMB 2.59 billion for the year ended December 31, 2024.

The board of directors attributes the revenue growth and the narrowing of the net loss primarily to the following factors: 1. The continuous enhancement of the company's quality management system governance, supported by information systems that enable intelligent manufacturing and smart supervision, has ensured a 100% pass rate for product batch release, thereby reducing sales costs. 2. Data-driven, precise marketing strategies and implementation, including real-time visual analysis of sales data using large models, targeted area segmentation, simulation exercises for strategy correction, and agile, differentiated policies, have improved the efficiency of marketing expenditure. This approach, combined with post-market evaluations in large populations, academic research on special groups such as pregnant women and patients with nephrotic syndrome, and academic promotion services covering terminal markets and consumers from provincial to local levels, has supported revenue growth while helping to reduce sales expenses. 3. The company's product distribution in 2025 expanded coverage to 232 disease control centers and 2,563 vaccination clinics, an increase from 2024. This broader vaccination channel network provided consumers with more regional choices for products, directly driving the growth in operating revenue. 4. While the group significantly increased listing expenses in 2025, the combined effect of revenue growth and tighter cost control measures, alongside ongoing research and development investment, has yielded initial results in cost reduction and efficiency gains, leading to a further narrowing of the net loss for the 2025 fiscal year.